These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 1994867)

  • 1. A controlled study of stanozolol in primary Raynaud's phenomenon and systemic sclerosis.
    Jayson MI; Holland CD; Keegan A; Illingworth K; Taylor L
    Ann Rheum Dis; 1991 Jan; 50(1):41-7. PubMed ID: 1994867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Raynaud's phenomenon by fibrinolytic enhancement.
    Jarrett PE; Morland M; Browse NL
    Br Med J; 1978 Aug; 2(6136):523-5. PubMed ID: 698554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood viscosity, Raynaud's phenomenon and the effect of fibrinolytic enhancement.
    Ayres ML; Jarrett PE; Browse NL
    Br J Surg; 1981 Jan; 68(1):51-4. PubMed ID: 7459607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
    Rademaker M; Cooke ED; Almond NE; Beacham JA; Smith RE; Mant TG; Kirby JD
    BMJ; 1989 Mar; 298(6673):561-4. PubMed ID: 2467711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ketanserin on Raynaud's phenomenon in progressive systemic sclerosis: a double-blind trial.
    Lukác J; Rovenský J; Tauchmannová H; Zitnan D
    Drugs Exp Clin Res; 1985; 11(9):659-63. PubMed ID: 3916837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial].
    Correa MJ; Mariz HA; Andrade LE; Kayser C
    Rev Bras Reumatol; 2014; 54(6):452-8. PubMed ID: 25458027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stanozolol as a novel therapeutic agent in dermatology.
    Helfman T; Falanga V
    J Am Acad Dermatol; 1995 Aug; 33(2 Pt 1):254-8. PubMed ID: 7622653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutaneous microcirculation in systemic sclerosis and response to intra-arterial reserpine.
    Nilsen KH; Jayson MI
    Br Med J; 1980 Jun; 280(6229):1408-11. PubMed ID: 7427134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ascorbic acid does not improve endothelium-dependent flow-mediated dilatation of the brachial artery in patients with Raynaud's phenomenon secondary to systemic sclerosis.
    Mavrikakis ME; Lekakis JP; Papamichael CM; Stamatelopoulos KS; Kostopoulos ChC; Stamatelopoulos SF
    Int J Vitam Nutr Res; 2003 Feb; 73(1):3-7. PubMed ID: 12690904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind study of prazosin in the treatment of Raynaud's phenomenon in scleroderma.
    Surwit RS; Gilgor RS; Allen LM; Duvic M
    Arch Dermatol; 1984 Mar; 120(3):329-31. PubMed ID: 6367665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.
    Kahan A; Amor B; Menkes CJ
    Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged improvement of Raynaud's phenomenon and scleroderma after recombinant tissue plasminogen activator therapy.
    Fritzler MJ; Hart DA
    Arthritis Rheum; 1990 Feb; 33(2):274-6. PubMed ID: 2106327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The peripheral vascular effects of nifedipine in Raynaud's syndrome associated with scleroderma: a double blind crossover study.
    Finch MB; Dawson J; Johnston GD
    Clin Rheumatol; 1986 Dec; 5(4):493-8. PubMed ID: 3816096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
    Bartolone S; Trifiletti A; De Nuzzo G; Scamardi R; Larosa D; Sottilotta G; Raffa A; Barbera N
    Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
    Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
    J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of phenformin and ethyloestrenol or stanozolol in the treatment of decreased fibrinolytic states. (Cutaneous vasculitis, Raynaud's disease, Behcet's syndrome, recurrent deep vein thrombosis and post myocardial infarction).
    Menon IS
    Acta Univ Carol Med Monogr; 1972; 52():19-23. PubMed ID: 4669824
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
    J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM; Korn JH; Csuka ME; Medsger TA; Rothfield NF; Ellman M; Martin R; Collier DH; Weinstein A; Furst DE; Jimenez SA; Mayes MD; Merkel PA; Gruber B; Kaufman L; Varga J; Bell P; Kern J; Marrott P; White B; Simms RW; Phillips AC; Seibold JR
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.